• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    12/28/23 4:31:10 PM ET
    $AQB
    $ARAY
    $CING
    $CPHI
    Meat/Poultry/Fish
    Consumer Staples
    Medical/Dental Instruments
    Health Care
    Get the next $AQB alert in real time by email

    Gainers

    • cbdMD (AMEX:YCBD) shares increased by 16.5% to $0.92 during Thursday's after-market session. The market value of their outstanding shares is at $2.7 million. The company's, Q4 earnings came out 4 days ago.
    • CEL-SCI (AMEX:CVM) shares increased by 8.7% to $3.09. The market value of their outstanding shares is at $154.2 million.
    • DermTech (NASDAQ:DMTK) stock moved upwards by 7.38% to $1.89. The company's market cap stands at $64.7 million.
    • China Pharma Holding (AMEX:CPHI) stock moved upwards by 6.55% to $0.13. The market value of their outstanding shares is at $4.2 million.
    • Accuray (NASDAQ:ARAY) shares rose 5.84% to $3.08. The market value of their outstanding shares is at $298.9 million.
    • Yield10 Bioscience (NASDAQ:YTEN) stock rose 5.08% to $0.25. The company's market cap stands at $2.9 million.

    Losers

    • Cingulate (NASDAQ:CING) shares declined by 14.9% to $8.33 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million.
    • Microbot Medical (NASDAQ:MBOT) shares fell 9.27% to $1.86. The company's market cap stands at $21.7 million.
    • T2 Biosystems (NASDAQ:TTOO) shares fell 8.06% to $6.85. The market value of their outstanding shares is at $27.7 million.
    • SenesTech (NASDAQ:SNES) stock declined by 7.52% to $1.6. The company's market cap stands at $1.2 million.
    • NKGen Biotech (NASDAQ:NKGN) shares fell 7.17% to $2.85. The market value of their outstanding shares is at $62.3 million.
    • AquaBounty Techs (NASDAQ:AQB) shares decreased by 6.15% to $2.75. The market value of their outstanding shares is at $10.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AQB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQB
    $ARAY
    $CING
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    Accuray Incorporated
    $ARAY
    2/13/2024$9.00Buy
    ROTH MKM
    Yield10 Bioscience Inc.
    $YTEN
    2/8/2024Buy → Hold
    Lake Street
    Cingulate Inc.
    $CING
    12/22/2023Buy → Hold
    Laidlaw
    DermTech Inc.
    $DMTK
    7/18/2022$48.00Outperform
    Oppenheimer
    Accuray Incorporated
    $ARAY
    6/23/2022$7.50Buy
    B. Riley Securities
    More analyst ratings

    $AQB
    $ARAY
    $CING
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, "Cingulate delivered on key inflection points throughout 2025 and this continues i

    3/18/26 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Microbot Medical® to Participate at the 38th Annual Roth Conference

    HINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA. The conference is a premier event that brings together growth companies, institutional investors, and industry leaders for presentations, panel discussions, and one-on-one meetings. Harel Gadot, CEO, President & Chairman of Microbot Medical will be presenting live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23rd. Mr. Gadot will highlight the Company's recent achievements, and how LIBERTY is

    3/17/26 8:40:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $AQB
    $ARAY
    $CING
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Microbot Medical with a new price target

    B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00

    2/10/26 8:01:31 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on Microbot Medical with a new price target

    Roth Capital initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.50

    12/3/25 8:38:40 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $ARAY
    $CING
    $CPHI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.

    SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)

    3/18/26 5:23:43 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form DEFA14A filed by Cingulate Inc.

    DEFA14A - Cingulate Inc. (0001862150) (Filer)

    3/18/26 4:30:04 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Cingulate Inc.

    10-K - Cingulate Inc. (0001862150) (Filer)

    3/18/26 8:13:46 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $ARAY
    $CING
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    EVP and CSO Silva Raul R. was granted 4,526 shares and covered exercise/tax liability with 1,828 shares, increasing direct ownership by 139% to 4,645 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:31 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO and CCO Patel Nilay Dahyabhai was granted 5,475 shares and covered exercise/tax liability with 2,086 shares (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:27 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $ARAY
    $CING
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $AQB
    $ARAY
    $CING
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

    SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th

    12/3/25 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AQB
    $ARAY
    $CING
    $CPHI
    Financials

    Live finance-specific insights

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $AQB
    $ARAY
    $CING
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials